Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
:CYBN
CYBN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.81 - $13.88
Previous Close$9.5
Volume184.55K
Average Volume (3M)383.24K
Market Cap
$1.42M
Enterprise ValueN/A
Total Cash (Recent Filing)$136.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Nov 17, 2025EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,023,630
10 Day Avg. Volume302,390
30 Day Avg. Volume383,238
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$93.00Price Target Upside1217.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCYB003’s 71% remission rate at 12 months following two 16 mg doses, coupled with its FDA Breakthrough Therapy Designation, underscore meaningful registration potential.
Financial FlexibilityThe recent announcement of a US$500 million convertible debenture facility—with US$50 million now funded—provides additional capital flexibility and extends runway beyond 2026.
Partnership ExpansionCybin has expanded its partnership with Thermo Fisher Scientific to include U.S.-based manufacturing of both CYB003 drug substance and capsules, supporting Phase 3 supply and future commercial scale-up.
Bears Say
Market ReactionThe trial achieved statistical significance on the primary endpoint, but CMPS stock reacted negatively and since this was a bellwether event for psychedelic stocks, the group, including Cybin, also traded down.
Stock ValuationCYBN still does not ascribe any value for CYB004 for generalized anxiety disorder in the valuation, viewing the product as not reflected in the stock in any appreciable way.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $4.81 and its highest was $13.88 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.42M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Nov 17, 2025 which is in 90 days.
How were Cybin’s earnings last quarter?
Currently, no data Available
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.91.
How many shares outstanding does Cybin have?
Cybin has 23,023,630 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
Company Description
Cybin
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CYBN Stock 12 Month Forecast
Average Price Target
$93.00
▲(1217.28% Upside)
Technical Analysis
Restart Life Sciences
―
Waverley Pharma
―
MYND Life Sciences
―
Awakn Life Sciences
―
Doseology Sciences
―